Quantitative determination of sst2 gene expression in neuroblastoma tumor predicts patient outcome

Journal of Clinical Endocrinology and Metabolism

Volumn 85, Issue 10, 2000, Pages 3866-3873

  Raggi, Claudia Casini ^a   Maggi, Mario ^a   Renzi, Daniela ^a   Calabrò, Antonino ^a   Bagnoni, Maria Letizia ^a   Scaruffi, Paola ^b   Tonini, Gian Paolo ^b   Pazzagli, Mario ^a   De Bernardi, Bruno ^c   Bernini, Gabriella ^a   Serio, Mario ^a   Orlando, Claudio ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c Gaslini's Children Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; RECEPTOR SUBTYPE; SOMATOSTATIN RECEPTOR;

ARTICLE; CANCER STAGING; DISEASE MARKER; GENE AMPLIFICATION; GENE EXPRESSION; GENETIC VARIABILITY; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; NEUROBLASTOMA; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL;

EID: 0033756786     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.85.10.3866     Document Type: Article

References (45)

1. Cancer incidence, survival and mortality for children under 15 years of age
2. Neuroblastoma
3. A proposed staging for children with neuroblastoma. Children's Cancer Study group A
4. Neuroblastoma
5. Serum ferritin as a guide to therapy in neuroblastoma
6. Serum neuron specific enolase in children with neuroblastoma. Relationship to stage and disease course
7. Serum lactate dehydrogenase in childhood neuroblastoma
8. Catecholamine metabolism in neuroblastoma
9. Allelic loss of chromosome 1 and additional chromosome 17 material are both unfavorable prognostic markers in neuroblastoma
10. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma
11. Association between high risk levels of expression of the TRK expression in non-advanced stages
12. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma
13. Association between high levels of expression of the multidrug resistance-associated protein (MRP) gene and poor outcome in primary human neuroblastoma
14. Evidence for nm23 RNA overexpression, DNA amplification and mutation in aggressive childhood neuroblastomas
15. CD44- A new prognostic marker for neuroblastoma
16. Correlating telomerase activity levels with human neuroblastoma outcomes
17. Quantitation of somatostatin receptor type 2 gene expression in neuroblastoma cell line and primary tumors using competitive reverse transcription-polymerase chain reaction
18. MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: The italian experience with 295 children
19. Amplification of MYCN in untreated human neuroblastomas correlates with advanced disease stage
20. Association of multiple copies of MYCN oncogene with rapid progression of neuroblastoma
21. Analysis of MYCN amplification in relation to disease stage and histologic types in human neuroblastomas
22. A comparative analysis of nuclear content and MYCN amplification in neuroblastoma
23. Combined analysis of DNA ploidy index and MYCN genomic content in neuroblastoma
24. Age-dependent prognostic significance of MYCN amplification in neuroblastoma
25. Combined determination of MYCN oncogene amplification and DNA ploidy in neuroblastoma
26. Polymerase chain reaction compared with dot blotting for the determination of MYCN amplification in neuroblastoma
27. Localized neuroblastoma: MYCN amplification is the main prognostic factor-results of the NBL 90 study
28. Prognostic prediction in neuroblastomas: Clinical significance of combined analysis for Ha-ras p21 expression and N-myc gene amplification
29. Identification, characterization and biological activity of somatostatin receptors in human neuroblastoma cell lines
30. Imaging of somatostatin receptors by indium-111-pentetreotide correlates with quantitative determination of somatostatin receptor type 2 gene expression in neuroblastoma tumors
31. Revisions in the international criteria for neuroblastoma diagnosis, staging, and response to treatment in patients with neuroblastoma
32. Gene amplification for c-erbB-2, c-myc, EGF receptor, int-2 and N-myc measured by quantitative PCR with a multiple competitor template
33. Image analysis in quantitative PCR. An application for the measurement of c-erbB-2 amplification in DNA from human tumors
34. In situ hybridization for procollagen types I, III, and IV mRNA in normal and fibrotic rat liver: Evidence for predominant expression in non-parenchymal liver cells
35. Expression of epidermal growth factor, transforming growth factor-β and their receptor in the human oesophagus
36. Non parametric estimation for incomplete observations
37. Statistical aspects of the analysis of data from retrospective studies of disease
38. Somatostatin receptors
39. Molecular and pharmacological characterization of somatostatin receptor subtypes in adrenal, extradrenal and malignant pheochromocytomas
40. Identification of somatostatin receptor subtypes and an implication of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors
41. Expression and localization of somatostatin receptor SSTR1, SSTR2 and SSTR3 messenger RNA in primary human tumors using in situ hybridization
42. Somatostatin in neuroblastoma and ganglioneuroma
43. Interrelationships between somatostatin sst2A receptors and somatostatin-containing axons in rat brain: Evidence for regulation of cell surface receptors by endogenous somatostatin
44. 1 cells
45. Gene therapy for pancreatic carcinoma: Local and distant antitumor effects after somatostatin receptor sst2 gene transfer